Detalles de la búsqueda
1.
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Lancet Oncol
; 24(3): 228-238, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36858721
2.
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Lancet Oncol
; 23(6): 768-780, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35489363
3.
Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Prostate
; 79(14): 1683-1691, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31442327
4.
Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
BMC Cancer
; 19(1): 766, 2019 Aug 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31382926
5.
A case of respiratory toxigenic diphtheria: contact tracing results and considerations following a 30-year disease-free interval, Catalonia, Spain, 2015.
Euro Surveill
; 23(13)2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29616610
6.
Echinocandins Compared to Fluconazole for Candidemia of a Urinary Tract Source: A Propensity Score Analysis.
Clin Infect Dis
; 64(10): 1374-1379, 2017 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28329281
7.
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.
BMC Cancer
; 16: 135, 2016 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-26906039
8.
Medical oncology workload, workforce census, and needs in Spain: two nationwide studies by the Spanish Society of medical oncology.
Clin Transl Oncol
; 26(1): 98-108, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37316754
9.
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial.
Clin Transl Oncol
; 26(6): 1532-1538, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38102374
10.
Efficacy and safety of a structured de-escalation from antipseudomonal ß-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial.
Lancet Infect Dis
; 24(4): 375-385, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38215770
11.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
J Clin Oncol
; 42(11): 1222-1228, 2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38227898
12.
Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.
Cancer Metastasis Rev
; 31 Suppl 1: S19-27, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22821550
13.
Impact of SARS-CoV-2 infection in pregnant women and their babies: clinical and epidemiological features.
Gac Sanit
; 37: 102332, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38007961
14.
SEOM SOGUG clinical guideline for treatment of kidney cancer (2022).
Clin Transl Oncol
; 25(9): 2732-2748, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37556095
15.
Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study.
Cancers (Basel)
; 15(21)2023 Oct 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37958398
16.
Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).
J Clin Oncol
; 41(14): 2493-2502, 2023 05 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36809050
17.
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
Front Oncol
; 13: 1223282, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37664025
18.
Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
Front Oncol
; 13: 1343027, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38495081
19.
Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib.
Clin Genitourin Cancer
; 21(3): e166-e174, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36610891
20.
Measures to evaluate quality of care in renal cancer: results of a Delphi study in Spain.
Clin Transl Oncol
; 24(3): 495-502, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34482526